SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

Ebanga

EBS·Emergent BioSolutions Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed (FDA approval December 21, 2020).
Why 3/10
Ebanga is already FDA-approved (December 2020) and commercially marketed with no pending PDUFA, pivotal readout, or other hard binary catalyst scheduled in the next 12 months. The most recent regulatory action was a supplemental BLA approval in February 2026, which is past. The drug is a modest part of Emergent's broader biodefense portfolio, so impactScore is 3.
Actionable Insight NEUTRAL

Ebanga is already approved and commercialized with no pending regulatory binary. The next material event would be any new BARDA procurement option exercise or a new outbreak-driven order, neither of which is predictable or scheduled. Watch Emergent's quarterly contracts-and-grants revenue line for Ebanga-related development work, which has been declining (down 60% year-over-year in Q3 2026).

Price Chart

Loading chart...

Executive Summary

Ebanga (ansuvimab-zykl, formerly mAb114) is a human monoclonal antibody approved by the FDA in December 2020 for treating Zaire ebolavirus (Ebola) infection in adults and children. Originally developed and approved by Ridgeback Biotherapeutics, Emergent BioSolutions (NYSE: EBS) took over US and Canada manufacturing, sales, and distribution under a July 2022 agreement. Emergent also holds a 10-year BARDA contract worth up to $704 million for Ebanga development and procurement. The drug competes with Regeneron's Inmazeb as one of only two FDA-approved Ebola treatments. For Emergent, Ebanga is a modest revenue contributor through government contracts and grants, with related development work declining in 2026. The drug has no upcoming binary catalysts, as it is already approved and commercially available.

How It Works

Ebanga is a monoclonal antibody, a lab-made protein designed to mimic the immune system's attack on the Ebola virus. It binds to a protein on the surface of the Zaire ebolavirus, blocking it from entering human cells and stopping the infection from spreading. It was developed from antibodies found in a survivor of the 1995 Ebola outbreak in the Democratic Republic of the Congo.

Trial Status

Ebanga was approved based on the PALM Phase 2/3 trial (NCT03719586), a multi-center, open-label, randomized controlled trial conducted during the 2018-2019 Ebola outbreak in the Democratic Republic of the Congo. The trial demonstrated improved survival versus a control investigational regimen. A supplemental BLA was approved in February 2026 updating the label with neutralization activity data against viral variants.

The Two-Sided Case

▲ Bull Case6
Ebanga is one of only two FDA-approved treatments for Ebola virus disease, giving it a unique position in biodefense and pandemic preparedness.
Emergent holds a 10-year BARDA contract worth up to $704 million for advanced development and procurement of Ebanga, providing a long-term government revenue stream (BARDA contract).
The WHO officially recommends Ebanga (alongside Inmazeb) for Ebola treatment, supporting global adoption and potential stockpiling by governments.
A supplemental BLA was approved in February 2026, updating the label with neutralization activity data against viral variants, keeping the product current.
Multiple institutional investors added or doubled positions in EBS in Q2 2026, including Millennium Management (doubled), Goldman Sachs (added), and Federated Hermes (added) (13F filings).
Analyst consensus is bullish: 5 Buy/Strong Buy ratings vs 1 Hold and 1 Sell, with a mean price target of $11 (61.5% implied upside from the $6.81 close) (analyst data).
▼ Bear Case5
Ebanga is a small and declining contributor to Emergent's revenue: Q3 2026 contracts and grants revenue fell 60% year-over-year, primarily due to lower Ebanga development work (Emergent Q3 2026 earnings).
The Ebola treatment market is tiny and outbreak-dependent; the drug's commercial opportunity is limited to government stockpiling and sporadic outbreaks.
Emergent faces competition from Regeneron's Inmazeb (REGN-EB3), the other FDA-approved Ebola monoclonal antibody, which was also tested in the same PALM trial.
Emergent's overall financials are under pressure: Q3 2026 revenue fell 52% year-over-year to $110M, GAAP gross margin dropped to 14%, and the company reduced its 2026 guidance (TradingKey).
Insider selling: Director Donald DeGolyer sold $126K worth of shares in October 2026 via a 10b5-1 plan (SEC filing).

Upcoming Catalysts

  • No scheduled binary catalysts (PDUFA, pivotal readout, or AdComm) are identified for Ebanga in the next 12 months. The drug is already approved and commercialized. Future catalysts would be tied to BARDA contract option exercises, new government procurement orders, or Ebola outbreak-related demand, none of which are on a fixed calendar.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Emergent BioSolutions Inc. 8-K EBS ·Originating report

Sources · 12

Hover a chip for the title
1 fda.gov2 ridgebackbio.com3 emergentbiosolutions.com4 cidrap.umn.edu5 marketscreener.com6 accessdata.fda.gov7 tradingkey.com8 investors.emergentbiosolutions.com9 healthpolicy-watch.news10 en.wikipedia.org11 drugs.com12 sec.gov